氟环丁氨酸(18F)PET-CT与MRI在前列腺切除术后复发前列腺癌检测中的前瞻性评估
24例非前列腺切除根治性治疗后生化失败患者(16/24曾接受近距离放疗)行氟环丁氨酸(18F)PET-CT与多参数MRI,以多学科真值小组结合组织学与临床随访(22.9±10.5个月)为参考标准。全身检出率PET-CT为94.7%(两位阅片者一致),mpMR为31.6%-36.8%。前列腺床PET-CT敏感度100.0%但特异度11.1%,mpMR敏感度15.4%-38.5%、特异度55.6%-77.8%;前列腺外病灶PET-CT诊断性能总体优于mpMR,阅片者间一致性也更高。
要点
- 非前列腺切除治疗后生化失败患者,氟环丁氨酸PET-CT全身检出率94.7%,mpMR仅31.6%-36.8%。
- 前列腺床PET-CT敏感度100.0%、特异度11.1%,mpMR敏感度15.4%-38.5%、特异度55.6%-77.8%。
- 前列腺外病灶PET-CT敏感度87.5%、特异度90.0%,mpMR敏感度50%-75%、特异度70%-80%。
核心结论
- 氟环丁氨酸PET-CT在非前列腺切除生化失败患者中全身检出率为94.7%,mpMR为31.6%-36.8%。
研究设计与样本
- 前瞻性研究,纳入24例非前列腺切除根治性治疗后生化失败患者,其中16/24曾接受近距离放疗,均行氟环丁氨酸(18F)PET-CT与mpMR,阅片者对患者病史、PSA及其他影像结果设盲。
诊断标准与关键数值
- 参考标准由多学科真值小组结合组织学与临床随访(22.9±10.5个月)建立,强调生化控制,真值小组对研究影像结果设盲。
- 前列腺床:22/24例符合参考标准(13例恶性、9例良性);氟环丁氨酸PET-CT两位阅片者敏感度100.0%、特异度11.1%、PPV 61.9%。
- 前列腺床:mpMR阅片者敏感度15.4%-38.5%、特异度55.6%-77.8%、PPV 50.0%-55.6%。
- 前列腺外病灶:18/24例符合参考标准;氟环丁氨酸PET-CT敏感度87.5%、特异度90.0%、PPV 87.5%。
- 前列腺外病灶:mpMR敏感度50%-75%、特异度70%-80%、PPV 57%-75%。
临床应用与阅片要点
- 氟环丁氨酸PET-CT全身检出率94.7%(两位阅片者一致),mpMR为31.6%-36.8%。
- 前列腺床氟环丁氨酸PET-CT敏感度高但特异度低,mpMR特异度较高但敏感度低。
- 氟环丁氨酸PET-CT前列腺区kappa 0.90、前列腺外区kappa 1.0;mpMR分别为0.25和0.74。
- 前列腺外病灶检测氟环丁氨酸PET-CT总体诊断性能优于mpMR。
- 氟环丁氨酸PET-CT阅片者间一致性高于mpMR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the disease detection rate, diagnostic performance and interobserver agreement of fluciclovine (18F) PET-CT and multiparametric magnetic resonance imaging (mpMR) in recurrent prostate cancer.
METHODS: Twenty-four patients with biochemical failure after non-prostatectomy definitive therapy, 16/24 of whom had undergone brachytherapy, underwent fluciclovine PET-CT and mpMR with interpretation by expert readers blinded to patient history, PSA and other imaging results. Reference standard was established via a multidisciplinary truth panel utilizing histology and clinical follow-up (22.9 ± 10.5 months) and emphasizing biochemical control. The truth panel was blinded to investigative imaging results. Diagnostic performance and interobserver agreement (kappa) for the prostate and extraprostatic regions were calculated for each of 2 readers for PET-CT (P1 and P2) and 2 different readers for mpMR (M1 and M2).
RESULTS: On a whole body basis, the detection rate for fluciclovine PET-CT was 94.7% (both readers), while it ranged from 31.6-36.8% for mpMR. Kappa for fluciclovine PET-CT was 0.90 in the prostate and 1.0 in the extraprostatic regions. For mpMR, kappa was 0.25 and 0.74, respectively. In the prostate, 22/24 patients met the reference standard with 13 malignant and 9 benign results. Sensitivity, specificity and positive predictive value (PPV) were 100.0%, 11.1% and 61.9%, respectively for both PET readers. For mpMR readers, values ranged from 15.4-38.5% for sensitivity, 55.6-77.8% for specificity and 50.0-55.6% for PPV. For extraprostatic disease determination, 18/24 patients met the reference standard. Sensitivity, specificity and PPV were 87.5%, 90.0% and 87.5%, respectively, for fluciclovine PET-CT, while for mpMR, sensitivity ranged from 50 to 75%, specificity 70-80% and PPV 57-75%.
CONCLUSION: The disease detection rate for fluciclovine PET-CT in non-prostatectomy patients with biochemical failure was 94.7% versus 31.6-36.8% for mpMR. For extraprostatic disease detection, fluciclovine PET-CT had overall better diagnostic performance than mpMR. For the treated prostate, fluciclovine PET-CT had high sensitivity though low specificity for disease detection, while mpMR had higher specificity, though low sensitivity. Interobserver agreement was also higher with fluciclovine PET-CT compared with mpMR.
引用
- Akin-Akintayo O, Tade F, Mittal P, et al. Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. Eur J Radiol. 2018. PMID: 29685521. doi:10.1016/j.ejrad.2018.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。